Evofem's Hormone-Free Contraceptive PHEXXI Heads to UAE Market Approval
Evofem Biosciences, Inc., a company dedicated to innovation in women's health, has taken a significant step forward in expanding the reach of its FDA-approved contraceptive product, PHEXXI®. Recently, the company announced its partnership with Pharma 1 Drug Store, a private health care provider in the United Arab Emirates (UAE), to submit an application for marketing approval with the UAE Ministry of Health and Prevention. This submission marks an important milestone for Evofem as it seeks to commercialize its products in international markets.
PHEXXI is a hormone-free contraceptive gel formulated from lactic acid, citric acid, and potassium bitartrate, designed to be used by women on-demand, just prior to intercourse. This unique product offers an alternative to traditional contraceptive methods, which often rely on hormonal components. Abdulwahab Atfah, CEO of Pharma 1 Drug Store, expressed optimism about the anticipated launch, recognizing a growing demand in the region for hormone-free options that cater to women’s reproductive needs. The target commercial launch in the UAE is planned for the first quarter of 2026.
Evofem’s CEO, Saundra Pelletier, highlighted the significance of this filing, emphasizing that it not only represents a path to diversifying the company’s revenue stream but also plays a crucial role in offering Emirati women access to reproductive health solutions that are effective yet free from systemic hormonal influences. PHEXXI operates by maintaining an optimal vaginal pH, which is inhospitable to sperm and certain pathogens, thus providing women with control over their contraceptive choices.
Pharma 1's exclusive rights to market PHEXXI across several Middle Eastern countries, including Saudi Arabia and Kuwait, enhances its capacity to meet regional healthcare demands. They are also responsible for regulatory compliance and the distribution of the product after approval. Since its establishment in 2019, Pharma 1 has successfully navigated the challenges of the healthcare market in the Gulf Cooperation Council (GCC) region, driven by a commitment to scientific evidence and consumer needs.
As Evofem works towards its UAE launch, it also has plans to continue growth through partnerships in other global markets. The company has seen significant sales growth over the past few years, bolstered by its product offerings that include PHEXXI and SOLOSEC, another FDA-approved treatment for bacterial vaginosis.
The launch of PHEXXI represents a innovative step not only in providing contraceptive options but also in addressing the broader needs of women’s reproductive health in the UAE and surrounding areas, aligning with Evofem’s mission to deliver safe and practical health solutions for women.
PHEXXI is a hormone-free contraceptive gel formulated from lactic acid, citric acid, and potassium bitartrate, designed to be used by women on-demand, just prior to intercourse. This unique product offers an alternative to traditional contraceptive methods, which often rely on hormonal components. Abdulwahab Atfah, CEO of Pharma 1 Drug Store, expressed optimism about the anticipated launch, recognizing a growing demand in the region for hormone-free options that cater to women’s reproductive needs. The target commercial launch in the UAE is planned for the first quarter of 2026.
Evofem’s CEO, Saundra Pelletier, highlighted the significance of this filing, emphasizing that it not only represents a path to diversifying the company’s revenue stream but also plays a crucial role in offering Emirati women access to reproductive health solutions that are effective yet free from systemic hormonal influences. PHEXXI operates by maintaining an optimal vaginal pH, which is inhospitable to sperm and certain pathogens, thus providing women with control over their contraceptive choices.
Pharma 1's exclusive rights to market PHEXXI across several Middle Eastern countries, including Saudi Arabia and Kuwait, enhances its capacity to meet regional healthcare demands. They are also responsible for regulatory compliance and the distribution of the product after approval. Since its establishment in 2019, Pharma 1 has successfully navigated the challenges of the healthcare market in the Gulf Cooperation Council (GCC) region, driven by a commitment to scientific evidence and consumer needs.
As Evofem works towards its UAE launch, it also has plans to continue growth through partnerships in other global markets. The company has seen significant sales growth over the past few years, bolstered by its product offerings that include PHEXXI and SOLOSEC, another FDA-approved treatment for bacterial vaginosis.
The launch of PHEXXI represents a innovative step not only in providing contraceptive options but also in addressing the broader needs of women’s reproductive health in the UAE and surrounding areas, aligning with Evofem’s mission to deliver safe and practical health solutions for women.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.